Should bevacizumab be continued after progression on bevacizumab in recurrent ovarian cancer?

被引：0
|
作者：
Backes, F. [1 ]
Richardson, D. [2 ]
McCann, G. [1 ]
Salani, R. [1 ]
Eisenhauer, E. [1 ]
Fowler, J. [1 ]
Copeland, L. [1 ]
Cohn, D. [1 ]
O'Malley, D. [1 ]
机构：
[1] Ohio State Univ, Columbus, OH 43210 USA
[2] Univ Texas SW, Dallas, TX USA
来源：
GYNECOLOGIC ONCOLOGY | 2012年 / 125卷
关键词：
D O I：
10.1016/j.ygyno.2011.12.226
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
225
引用
收藏
页码：S94 / S94
页数：1
相关论文
共 50 条
  • [1] Should Bevacizumab Be Continued After Progression on Bevacizumab in Recurrent Ovarian Cancer?
    Backes, Floor J.
    Richardson, Debra L.
    McCann, Georgia A.
    Smith, Blair
    Salani, Ritu
    Eisenhauer, Eric L.
    Fowler, Jeffrey M.
    Copeland, Larry J.
    Cohn, David E.
    O'Malley, David M.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2013, 23 (05) : 833 - 838
  • [2] Should Bevacizumab Be Continued Beyond Progression in Colorectal Cancer?
    Grothey, Axel
    Arnold, Dirk
    Ellis, Lee M.
    CURRENT COLORECTAL CANCER REPORTS, 2008, 4 (03) : 139 - 143
  • [3] Recurrent colon perforation after discontinuation of bevacizumab for ovarian cancer
    Nonaka, Michiko
    Sato, Seiya
    Osaku, Daiken
    Sawada, Mayumi
    Kudoh, Akiko
    Chikumi, Jun
    Sato, Shinya
    Oishi, Tetsuro
    Harada, Tasuku
    GYNECOLOGIC ONCOLOGY REPORTS, 2018, 26 : 21 - 23
  • [4] Continuous Administration of Bevacizumab After Disease Progression in Recurrent Ovarian Cancer: A Retrospective Observational Study
    Tanigawa, Terumi
    Matoda, Maki
    Omi, Makiko
    Aoki, Yoichi
    Netsu, Sachiho
    Nomura, Hidetaka
    Okamoto, Sanshiro
    Omatsu, Kohei
    Yunokawa, Mayu
    Kanao, Hiroyuki
    Takeshima, Nobuhiro
    ANTICANCER RESEARCH, 2020, 40 (09) : 5285 - 5290
  • [5] Bevacizumab beyond progression: Impact of subsequent bevacizumab retreatment in patients with ovarian, fallopian tube, and peritoneal cancer after progression.
    Previs, Rebecca Ann
    Spinosa, Daniel
    Fellman, Bryan M.
    Lorenzo, Amelia
    Mulder, Isabelle
    Mahmoud, May
    Enbaya, Ahmed
    Hansen, Jean M.
    Cobb, Lauren Patterson
    Soliman, Pamela T.
    Coleman, Robert L.
    Secord, Angeles Alvarez
    Westin, Shannon Neville
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [6] Bevacizumab after bevacizumab in platinum-sensitive recurrent ovarian cancer: A subgroup analysis of GOG0213.
    Coleman, Robert L.
    Brady, Mark F.
    Herzog, Thomas J.
    Armstrong, Deborah Kay
    Sabbatini, Paul
    Walker, Joan L.
    Kim, Byoung
    Fujiwara, Keiichi
    Tewari, Krishnansu Sujata
    O'Malley, David M.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [7] Sustained progression-free survival with weekly paclitaxel and bevacizumab in recurrent ovarian cancer
    Hurt, J. D.
    Richardson, D. L.
    Seamon, L. G.
    Fowler, J. F.
    Copeland, L. J.
    Cohn, D. E.
    Eisenhauer, E.
    Salani, R.
    O'Malley, D. M.
    GYNECOLOGIC ONCOLOGY, 2009, 115 (03) : 396 - 400
  • [8] Sustained progression-free survival with weekly paclitaxel and bevacizumab in recurrent ovarian cancer
    Hurt, J. D.
    Richardson, D. L.
    Seamon, L. G.
    Cohn, D. E.
    Fowler, J. M.
    Copeland, L. J.
    O'Malley, D. M.
    Eisenhauer, E. L.
    Salani, R.
    GYNECOLOGIC ONCOLOGY, 2009, 112 (02) : S154 - S155
  • [9] Bevacizumab beyond progression: Impact of subsequent bevacizumab re-treatment in patients with ovarian, fallopian tube, and peritoneal cancer after progression
    Asare, Amma
    Previs, Rebecca Ann
    Spinosa, Daniel
    Fellman, Bryan
    Scott, Amelia L.
    Mulder, Isabelle
    Mahmoud, Y.
    Enbaya, Ahmed
    Siedel, Jean Hansen
    Cobb, Lauren
    Solima, Pamela T.
    Sood, Anil K.
    Coleman, Robert L.
    Secord, Angeles Alvarez
    Westin, Shannon N.
    GYNECOLOGIC ONCOLOGY, 2025, 194 : 112 - 118
  • [10] Bladder perforation in a patient with recurrent epithelial ovarian cancer after treatment with bevacizumab
    Bansal, Nisha
    Hoffman, Mitchell
    GYNECOLOGIC ONCOLOGY, 2011, 120 (02) : 313 - 314
12345